BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 HKD | -5.59% |
|
+8.00% | -40.79% |
| May. 15 | Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China | MT |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 |
Presenter SpeechChris Fang (Executives)Good day, everyone, and thank you for standing by. Welc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.327
CNY
Average target price
4.314
CNY
Spread / Average Target
+225.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.79% | 134M | |
| +9.48% | 115B | |
| +12.90% | 107B | |
| -13.83% | 22.31B | |
| -3.52% | 21.6B | |
| -4.84% | 18.23B | |
| -38.57% | 17.62B | |
| +7.21% | 14.26B | |
| +34.73% | 12.37B | |
| -26.61% | 8.28B |
- Stock Market
- Equities
- 2137 Stock
- News Brii Biosciences Limited
- Transcript : Brii Biosciences Limited, Q2 2022 Earnings Call, Aug 24, 2022
